Slate Medicines’ Merger and $245M Private Placement Fuel Mission in Migraine

Migraine drugs developer Slate Medicines is going public in a reverse merger with Fulcrum Therapeutics. The biotech’s lead antibody drug blocks two novel migraine targets, offering the potential for better efficacy compared to other next-generation migraine drugs in R&D. The post Slate Medicines’ Merger and $245M Private Placement Fuel Mission in Migraine appeared first on…

Read More

Biden’s cancer diagnosis should be a teaching moment

By DANIEL STONE Joe Biden’s metastatic cancer diagnosis brings together two controversial issues: PSA testing for prostate cancer and presidential politics. To understand what is at stake Americans need basic information about PSA testing, and a frank discussion of the reasoning behind the prostate cancer screening decisions in the former president’s case. The dribble of…

Read More